Camp4 Details ASCEND Phase 1/2 Trial Design; First Patient Dosing Expected by Year-End
CAMP sits 37% above its 52-week low of $2.81.
Summary
Camp4 Therapeutics unveiled detailed design for its ASCEND Phase 1/2 trial of CMP-002 in SYNGAP1-related disorder, with first patient dosing expected by end of 2026 and topline data in the first half of 2028. The company also disclosed a new SHANK3 program for Phelan-McDermid Syndrome.
Key Events · Product Development and Regulatory · CAMP
-
ASCEND Trial Design Detailed
Phase 1/2 randomized, double-blind, placebo-controlled MAD study with 3:1 randomization to intrathecal CMP-002 or sham pinprick; three cohorts with minimum 8 participants each; ~10 months per participant.
-
First Patient Dosing by Year-End
Company expects to dose first patient in ASCEND by end of 2026, with topline data readout targeted for first half of 2028.
-
Global Trial Footprint
Sites approved in UK, Australia, and Argentina; EU sites under review; planned >11 sites across at least 9 countries.
-
New SHANK3 Pipeline Program
Company disclosed preclinical SHANK3 program for Phelan-McDermid Syndrome (>45,000 US patients), with development candidate expected in 2027; two additional early-stage CNS haploinsufficiency programs also disclosed.
Analysis · CAMP · Life Sciences
Camp4 Therapeutics provided the first detailed look at its ASCEND Phase 1/2 trial for CMP-002 in SYNGAP1-related disorder, including specific inclusion criteria, dosing schedule, and a topline data readout targeted for the first half of 2028. The company also disclosed a new SHANK3 program for Phelan-McDermid Syndrome with a development candidate expected in 2027. This is the most concrete clinical roadmap the company has shared since securing regulatory clearances in Australia, the UK, and Argentina, and it sets clear milestones investors can track.
How filings like this one have moved
In the 30 days to Nov 1, 2026, 32.5% of the 1969 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CAMP was trading at $3.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $241.6M. The 52-week trading range was $2.81 to $7.75. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.